- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Boehringer Ingelheim Expands AI Partnership with OpenProtein.AI
The companies will co-develop integrated workflows for next-generation therapeutic development.
Mar. 31, 2026 at 1:16pm
Got story updates? Submit your updates here. ›
An abstract visualization of the AI-powered workflows that are accelerating the development of next-generation therapeutics.NYC TodayBoehringer Ingelheim has expanded its collaboration with OpenProtein.AI following a successful initial deployment. The two companies will work together to co-develop integrated workflows for next-generation therapeutic development using OpenProtein.AI's AI-driven antibody discovery platform.
Why it matters
This expanded partnership highlights the growing importance of AI and machine learning in the pharmaceutical industry, particularly for accelerating the development of new therapeutic candidates. Boehringer Ingelheim's decision to deepen its relationship with OpenProtein.AI signals the platform's potential to streamline and optimize the protein engineering process.
The details
Under the expanded agreement, Boehringer Ingelheim and OpenProtein.AI will work to integrate the AI company's platform into Boehringer's existing workflows for therapeutic development. This will allow the pharmaceutical giant to leverage OpenProtein.AI's capabilities in areas like protein structure prediction and antibody design to enhance its pipeline of next-generation treatments.
- The initial collaboration between the two companies was successfully deployed in 2025.
- The expanded partnership was announced on March 31, 2026.
The players
Boehringer Ingelheim
A leading global pharmaceutical company that develops innovative therapies for a variety of diseases.
OpenProtein.AI
An AI-driven biotechnology company that specializes in protein engineering and antibody discovery.
The takeaway
This expanded partnership between Boehringer Ingelheim and OpenProtein.AI underscores the growing importance of AI-powered tools in the pharmaceutical industry, as companies seek to streamline and optimize the development of new therapeutic candidates.
